ArticleLeukemia & lymphoma2013
Examining racial differences in diffuse large B-cell lymphoma presentation and survival.
Article in Leukemia & lymphoma, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials: a systematic review.The oncologist · 2025Pooled it
- Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.Cancer chemotherapy and pharmacology · 2020Trial
- Article
- Article
- Comparative Outcomes Between Black and White Patients With Early-Stage Diffuse Large B-Cell Lymphoma.Cancer medicine · 2026Observational
- Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.Blood cancer discovery · 2025Review
- Lymphoma Imaging in HIV and Non-HIV Patients: A Retrospective Cross-Sectional Study With Clinical and Pathological Correlation.Cancer informatics · 2025Article
- Racial and ethnic disparities in outcomes of diffuse large B cell lymphoma in adolescent and young adults: a SEER database analysis.Annals of hematology · 2024Article
- Association between low incidence of TP53 mutations and reduced early relapse rates in Uygur DLBCL.Annals of hematology · 2024Article
- Association of race/ethnicity and insurance with survival in patients with diffuse large B-cell lymphoma in a large real-world cohort.Cancer medicine · 2024Article
- Article
- Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma.Journal of hematology · 2022Article
- Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort.Experimental hematology & oncology · 2021Article
- Perceptions of clinical care and research among African-American patients with lymphoma.Leukemia & lymphoma · 2021Article
- Associations between race and survival in pediatric patients with diffuse large B-cell lymphoma.Cancer medicine · 2021Article
- Article
- PET-derived tumor metrics predict DLBCL response and progression-free survival.Leukemia & lymphoma · 2019Article
- Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study.Leukemia & lymphoma · 2019Article
- A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.Cancer · 2019Article
- Incidence and Mortality Trends and Risk Prediction Nomogram for Extranodal Diffuse Large B-Cell Lymphoma: An Analysis of the Surveillance, Epidemiology, and End Results Database.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 1 country.
Funding
Abstract
We performed a retrospective cohort analysis of 701 (533 white and 144 black) patients with diffuse large B-cell lymphoma (DLBCL) treated at two referral centers in southern United States between 1981 and 2010. Median age of diagnosis for blacks was 50 years vs. 57 years for whites (p < 0.001). A greater percentage of blacks presented with elevated lactate dehydrogenase levels, B-symptoms and performance status ≥ 2. More whites (8%) than blacks (3%) had a positive family history of lymphoma (p = 0.048). There were no racial differences in the use of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; 52% black vs. 47% white, p = 0.73). While black race predicted worse survival among patients treated with CHOP (hazard ratio [HR] 1.8, p < 0.001), treatment with R-CHOP was associated with improved survival irrespective of race (HR 0.61, p = 0.01). Future studies should examine biological differences that may underlie the observed racial differences in presentation and outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.